跳至主要内容
临床试验/DRKS00003624
DRKS00003624招募中3 期

Early Prospective Therapy Trial to Delay Renal Failure in Children with Alport Syndrome - EARLY PRO-TECT Alport

niversitätsmedizin Göttingen0 个研究点目标入组 120 人开始时间: 2012年3月23日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
24 Months 至 17 Years(—)
性别
All

入选标准

  • Definitive diagnosis of Alport syndrome: Kidney biopsy (patient or affected relative/s), and/or mutation analysis (hemizygous X-chromosomal or homozygous autosomal-recessive) and assessment of criteria for clinical diagnosis (haematuria, positive family history regarding kidney diseases, ocular changes, labyrinthine hearing loss)
  • - Alport syndrome levels 0 or I at screening (microhaematuria without microalbuminuria or microalbuminuria [30-300 mg albumin/gCrea]).
  • - Aged between =24 months and <18 years at screening
  • - Assent from patient and informed consent from parents/legal guardian

排除标准

  • - Uncertain diagnosis or variants of Alport syndrome such as a heterozygous carrier
  • - Alport syndrome levels II, , III, or IV (albuminuria >300 mg/g Crea, creatinine clearance <60 mL/min, or end stage renal failure [ESRF])
  • - Known allergies or intolerances to ramipril or related compounds
  • - Known contraindication for ACEi-therapy
  • - Additional chronic renal, pulmonary or cardiac diseases
  • - Pregnancy and lactation

研究者

发起方
niversitätsmedizin Göttingen

相似试验